Catching respiratory illnesses early is crucial to prevent their spread and get proper treatment. This study explored the potential of using wearable sensors and self-reported symptoms to prompt people to test themselves for common viruses at home. We found that this approach holds promise for early detection, but also identified areas for improvement before widespread use.
Quickly identifying respiratory infections like COVID-19 and RSV is key to controlling their spread. Traditionally, this involves visiting a doctor's office or clinic. However, a new approach is gaining traction: home testing. This study investigated whether wearable sensors and self-reported symptoms could trigger timely home testing for these viruses.
We conducted a decentralized, randomized controlled trial involving 450 participants in the US. Participants were randomly assigned to one of three groups:
Group 1: Received a wearable sensor (Fitbit Sense) and could be prompted to take home tests based on changes in their physiological data or self-reported symptoms.
Group 2: Received a wearable sensor and home tests, triggered only by symptoms.
Group 3: Control group with no wearable sensors or home tests.
The primary goal was to assess the feasibility of prompting home testing based on wearable data or symptoms and to measure how many participants actually used the home tests.
The trial successfully recruited and randomized participants.
Over half (52%) were from underrepresented groups in research.
Among those who received home tests (Groups 1 and 2), 39% were prompted to test.
More prompts were triggered by symptoms (68%) than wearable data (32%).
Out of those prompted, 52% successfully performed the home test.
Of those tested, 31% were positive for a virus (all SARS-CoV-2).
Notably, there were no adverse events related to the testing approach.
This study demonstrates the early feasibility of a program prompting home testing for respiratory viruses based on both symptoms and wearable data. However, areas for improvement were identified:
Wearable sensors need better refinement to trigger testing more effectively.
Strategies to increase participation rates in-home testing are necessary.
This study paves the way for utilizing wearable sensors and home testing to identify respiratory viruses. Further research will focus on optimizing technology and participant engagement to facilitate wider implementation of this promising approach.
Quer G, Coughlin E, Villacian J, et al. Feasibility of wearable sensor signals and self-reported symptoms to prompt at-home testing for acute respiratory viruses in the USA (DETECT-AHEAD): a decentralized, randomized controlled trial. Lancet Digit Health. 2024;6(8):e546-e554. doi:10.1016/S2589-7500(24)00096-7
1.
AI-based liquid biopsy shows promise for detecting brain cancer
2.
Obesity linked to subsequent neoplasms in childhood cancer survivors
3.
Reducing social media to an hour a day boosts young people's self-image.
4.
Prostate Cancer Treatment Associated With Long-Term Complications
5.
Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.
1.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
2.
Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells
3.
Hope in Numbers: Understanding AML Leukemia Survival Rates and Emerging Therapies
4.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
5.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Current Scenario of Cancer- Q&A Session to Close the Gap
4.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation